| Generic Name |
Bendamustine hydrochloride |
| Brand Name |
Belrapzo® |
| Payment Category |
Medicare Part B |
| Year Introduced |
2019 |
| Type of Drug |
Alkylating agent |
| Manufacturer |
Eagle Pharmaceuticals |
| Medical Affairs Questions (date verified) |
919.328.5975 |
| Coverage & Reimbursement Questions |
833.324.5322 |
| HCPCS |
J9036 |
| Billing Unit |
1 mg |
| Medicare Payment Limit (Effective January 1, 2021) |
$22.27 |
FDA-Approved Indication(s)
- Indicated for the treatment of patients with 1) chronic lymphocytic leukemia or 2) indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. (5/08/19)
|
| Approved Indication(s) with Orphan Drug Status |
1) Treatment of chronic lymphocytic leukemia. 2) Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma) |
| ICD-10 Code(s) for Labeled Indication(s) |
Chronic lymphocytic leukemia [C91.1x]; Unspecified B-cell lymphoma [C84.1x] |
